Navigation Links
NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting
Date:2/18/2011

ROCKVILLE, Md., Feb. 18, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biopharmaceutical company, today presented the final safety and immunogenicity results from its 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine clinical trial in Mexico at the invitation-only 7th World Health Organization Meeting (WHO) on Evaluation of Pandemic Influenza Vaccines in Clinical Trials. The meeting was held at the WHO headquarters in Geneva, Switzerland where Dr. Gregory Glenn, Chief Medical Officer of Novavax, presented the findings at a session entitled: "Pandemic and Potentially Pandemic Vaccines Developed Using New Technologies."  Dr. Glenn's presentation was entitled: "Phase II randomized, double-blind, placebo-controlled trial of a novel (H1N1) influenza VLP vaccine" and is available at www.novavax.com under the Investors/Events tab.

In this randomized, double-blind, placebo-controlled Phase II trial, Novavax's H1N1 VLP vaccine was administered in a single-dose regimen to over 3,000 subjects. The study found that the vaccine exceeded the immunogenicity criteria for seasonal influenza vaccine licensure at all dose levels including the 5mcg dose. Additionally, a single administration of the VLP vaccine induced high levels of hemaglutinin inhibition (HAI) titers in subjects without pre-existing detectable immunity to this pandemic influenza strain. Together, the data indicate that the H1N1 VLP vaccine was well-tolerated and immunogenic.

Dr. Glenn commented:  "This trial was an important milestone for our influenza vaccine program and demonstrated the potential of our recombinant vaccine technology.  The data indicate that our VLP vaccine was well-tolerated and generated robust immunogenicity at all dose levels, including the 5mcg dose. The single-dose seroprotection data in patients who had no pre-existing immunity (seronegatives) achieved protective titers in up
'/>"/>

SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NOVAVAX to Present H1N1 VLP Influenza Vaccine Clinical Data at 7th World Health Organization (WHO) Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials
2. NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial
3. NOVAVAX to Present at Lazard 7th Annual Healthcare Conference
4. NOVAVAX Reports Third Quarter 2010 Financial Results
5. Novavax to Report Third Quarter 2010 Financial Results on November 5, 2010
6. NOVAVAX to Present at BIO Investor Forum
7. NOVAVAX to Present at Stifel Nicolaus Conference
8. NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures
9. NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines
10. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2010
11. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... NEW YORK, Oct. 6, 2011 Avista Capital Partners, ... has hired Hakan Bjorklund, the departing Chief Executive Officer ... closely with Avista on the development of Nycomed during ... to Takeda Pharmaceuticals Company Limited for Euro 9.6 billion. ...
... Scios Inc. announced an agreement with the United States Department ... a prescription medication for patients with heart failure. ... guilty plea to a single misdemeanor violation of the Food, ... million fine. Scios acknowledges that NATRECOR® was misbranded ...
Cached Medicine Technology:Avista Capital Partners Appoints Hakan Bjorklund as Healthcare Operating Executive 2Avista Capital Partners Appoints Hakan Bjorklund as Healthcare Operating Executive 3
(Date:4/22/2014)... The latest scientific advances and emerging therapies in heart ... main annual meeting of the Heart Failure Association (HFA) ... also hear breaking news on acute heart failure during ... is part of the main congress. , The event ... the Megaron Athens International Conference Centre (MAICC). The full ...
(Date:4/22/2014)... 10 Americans support mandated coverage of birth control medications, ... the University of Michigan Health System. , Women, blacks, ... at home, and adults with private or public insurance ... universal coverage of birth control medications, according to the ... American Medical Association ( JAMA ). , Individuals ...
(Date:4/22/2014)... In parallel with modern man ( Homo sapiens ), there ... lived side by side, such as Neanderthals and the recently ... survived. What was it in our genetic makeup that ... is known about our unique genetic makeup as distinguished from ... that we are the only species among them ,to survive. ...
(Date:4/22/2014)... serious health conditions may be influenced by low exposure ... A study has revealed how men,s testosterone levels may ... some men have less of the hormone than others ... Low levels of the hormone have been linked ... shown that the cells responsible for producing testosterone in ...
(Date:4/22/2014)... more likely to have a child who develops an ... recent study from researchers from the Drexel University School ... Sweden provides more insight into how the risk associated ... and found that the risk of having a child ... older parents., In the study, published in the February ...
Breaking Medicine News(10 mins):Health News:The world's largest heart failure congress 2Health News:The world's largest heart failure congress 3Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:What gave us the advantage over extinct types of humans? 2Health News:Child's autism risk accelerates with mother's age over 30 2Health News:Child's autism risk accelerates with mother's age over 30 3
... Lab Internacional,S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or ... March 31, 2009. All figures included herein,were prepared ... nominal,Mexican pesos. Also, the following consolidated figures show the ... , , 1Q09 Highlights (vs. 1Q08), ...
... April 28 Claimsnet.com inc. (OTC ... solutions for the healthcare industry, today reported its results ... March 31, 2009.For the quarter ended March 31, 2009, ... from the $490,000 reported for the first quarter of ...
... The American Physical Society commends President Obama,s commitment to ... implementing policies that will enhance science and math ... 3 percent of the nation,s gross domestic product to ... ensure that the U.S. develops effective solutions to challenges ...
... battle swine flu epidemicWASHINGTON, April 28 Transportation Security Officers ... precautionary measures as they screen passengers who may have been ... Employees said today.In an urgent letter to TSA Acting Administrator ... , That a respirator, ...
... The President of the American Academy of Disaster Medicine,s ... and analysis from a disaster medicine perspective on the ... explanation of why improvements are needed to the U.S. ... any virus or pathogen; how disaster medicine specialists are ...
... CLEVELAND, April 28 DATATRAK International, Inc. (Nasdaq: ... on global eClinical solutions for the clinical trials industry, ... CRO, has become the newest member of the DATATRAK ... growing list of CROs, CPI is able to expand ...
Cached Medicine News:Health News:Genomma Lab Internacional Announces First Quarter 2009 Results 2Health News:Genomma Lab Internacional Announces First Quarter 2009 Results 3Health News:Claimsnet.com Reports First Quarter 2009 Results 2Health News:Claimsnet.com Reports First Quarter 2009 Results 3Health News:APS commends President Obama's commitment to greater investment in science 2Health News:AFGE: TSA Must Do More to Protect Its Workforce and the Public 2Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 2Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 3Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 4Health News:German CRO clinicalprojects international GmbH Becomes Newest Member of DATATRAK's CRO Connect Program(TM) 2Health News:German CRO clinicalprojects international GmbH Becomes Newest Member of DATATRAK's CRO Connect Program(TM) 3Health News:German CRO clinicalprojects international GmbH Becomes Newest Member of DATATRAK's CRO Connect Program(TM) 4
... The CELL-DYN 1800 is the latest ... technology used since the founding of the ... QC and data management capabilities, the CELL-DYN ... labs. The CELL-DYN 1800 is smaller than ...
... Precision Net Point-of-Care Data Networking ... the power of data networking. In ... results can be transferred from nursing ... laboratory. Data is instantly available to ...
... EarlyDetect® Menopause Test is a one ... menopause has occured. This test can ... follicle-stimulating hormone (FSH), which indicates whether ... simple to use and in a ...
... Teco Diagnostics manufactures fine urine chemistry ... urine chemistry reagent strips from start ... offer more economical prices compared to ... quality. Teco Diagnostics urine reagent strips ...
Medicine Products: